These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 21286668

  • 1. Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma.
    Wang Y, Chen J, Li X, He Y, Hu B, Ji C, Xu J.
    Oncol Rep; 2011 Apr; 25(4):1047-52. PubMed ID: 21286668
    [Abstract] [Full Text] [Related]

  • 2. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
    Rumiato E, Cavallin F, Boldrin E, Cagol M, Alfieri R, Basso D, Castoro C, Ancona E, Amadori A, Ruol A, Saggioro D.
    Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
    [Abstract] [Full Text] [Related]

  • 3. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE, Danenberg PV, Harpole DH.
    Clin Cancer Res; 2005 Mar 15; 11(6):2215-21. PubMed ID: 15788669
    [Abstract] [Full Text] [Related]

  • 4. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D.
    Clin Lung Cancer; 2009 Mar 15; 10(2):118-23. PubMed ID: 19362955
    [Abstract] [Full Text] [Related]

  • 5. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Cespedes M.
    J Clin Oncol; 2006 Sep 10; 24(26):4333-9. PubMed ID: 16896002
    [Abstract] [Full Text] [Related]

  • 6. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
    Chen C, Wang F, Wang Z, Li C, Luo H, Liang Y, An X, Shao J, Li Y.
    Cancer Chemother Pharmacol; 2013 Aug 10; 72(2):315-22. PubMed ID: 23712330
    [Abstract] [Full Text] [Related]

  • 7. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
    Hwang IG, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ.
    Cancer Chemother Pharmacol; 2011 Oct 10; 68(4):935-44. PubMed ID: 21298384
    [Abstract] [Full Text] [Related]

  • 8. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV.
    J Am Coll Surg; 2005 Mar 10; 200(3):336-44. PubMed ID: 15737843
    [Abstract] [Full Text] [Related]

  • 9. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
    Hejna M, Kornek GV, Schratter-Sehn AU, Zach M, Schoder M, Raderer M, Rosen H, Schiessel R, Scheithauer W.
    Cancer; 1996 Oct 15; 78(8):1646-50. PubMed ID: 8859175
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.
    Am J Clin Oncol; 2009 Feb 15; 32(1):38-43. PubMed ID: 19194123
    [Abstract] [Full Text] [Related]

  • 11. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun 15; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 12. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 15; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 13. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct 15; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 14. Neoadjuvant chemotherapy in squamous cell carcinoma of the esophagus using low dose continuous infusion 5-fluorouracil and cisplatin: results of a prospective study.
    Aroori S, Parshad R, Kapoor A, Gupta SD, Kumar A, Chattophadyay TK.
    Indian J Cancer; 2004 Oct 15; 41(1):3-7. PubMed ID: 15105572
    [Abstract] [Full Text] [Related]

  • 15. The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma.
    Iizuka N, Hirose K, Noma T, Hazama S, Tangoku A, Hayashi H, Abe T, Yamamoto K, Oka M.
    Br J Cancer; 1999 Oct 15; 81(3):469-75. PubMed ID: 10507772
    [Abstract] [Full Text] [Related]

  • 16. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P.
    Clin Cancer Res; 2007 Jul 01; 13(13):3855-9. PubMed ID: 17606717
    [Abstract] [Full Text] [Related]

  • 17. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.
    Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Yamamoto M.
    Int J Oncol; 2008 May 01; 32(5):1091-6. PubMed ID: 18425336
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
    Lee J, Lee KE, Im YH, Kang WK, Park K, Kim K, Shim YM.
    Ann Thorac Surg; 2005 Oct 01; 80(4):1170-5. PubMed ID: 16181835
    [Abstract] [Full Text] [Related]

  • 19. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 20. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M.
    J Clin Oncol; 2007 Apr 01; 25(10):1247-54. PubMed ID: 17401013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.